Wednesday, 26 August 2026European Markets

XILAM ANIMATION Stock 17.09% Up On Thursday

Loading stream...

(vianews) - the market ended the session with xilam animation (xil.pa) jumping 17.09% to €5.48 on thursday while cac 40 rose 1.13% to €7,401.35.

xilam animation's last close was €4.68, 86.85% below its 52-week high of €35.60.

about xilam animation

xilam animation operates as an audiovisual production company in france and internationally. the company creates, produces, and distributes original programs for children and adults. it also broadcasts content on television; subscription video on demand streaming platforms, including netflix, disney +, amazon, and nbc universal; and advertising video on demand streaming platforms, such as youtube and facebook. in addition, the company produces animated, series, mini-series, and feature films. it owns the oggy, cockroaches, zig & sharko, chicky, oggy oggy in preschool, oggy next gen, les tales of lupin, moka, mr magoo, trico, and i lost my body brands. the company was incorporated in 1999 and is headquartered in paris, france.

earnings per share

as for profitability, xilam animation has a trailing twelve months eps of €0.08.

pe ratio

xilam animation has a trailing twelve months price to earnings ratio of 68.5. meaning, the purchaser of the share is investing €68.5 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.96%.

more news about xilam animation (xil.pa).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com